KBC Group
BEAM icon

KBC Group’s Beam Therapeutics BEAM Stock Holding History

KBC Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85K Hold
3,569
– – ﹤0.01% 1417
2025
Q4 		$99K Hold
3,569
– – ﹤0.01% 1284
2025
Q3 		$87K Buy
3,569
+1,535
+75% +$30.5K ﹤0.01% 1347
2025
Q2 		$35K Sell
2,034
-2,109
-51% -$36.7K ﹤0.01% 1686
2025
Q1 		$81K Hold
4,143
– – ﹤0.01% 1591
2024
Q4 		$103K Buy
4,143
+2,104
+103% +$53.7K ﹤0.01% 1536
2024
Q3 		$50K Hold
2,039
– – ﹤0.01% 1705
2024
Q2 		$48K Buy
2,039
+244
+14% +$5.99K ﹤0.01% 1643
2024
Q1 		$59K Hold
1,795
– – ﹤0.01% 1450
2023
Q4 		$49K Buy
1,795
+620
+53% +$15.4K ﹤0.01% 1536
2023
Q3 		$28K Buy
+1,175
New +$31.5K ﹤0.01% 1807

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

KBC Group's BEAM Position: Q1 2026 in Review

KBC Group held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 3,569 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

KBC Group first reported a position in BEAM in Q3 2023 and has held it in 11 quarters since. The position peaked at $103K in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • KBC Group held 3,569 shares of Beam Therapeutics worth $85K as of Q1 2026.
  • KBC Group left its Beam Therapeutics share count unchanged in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1417 holding.
  • KBC Group first reported a position in Beam Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Beam Therapeutics position peaked at $103K in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.